Sharon Smith

Chinese herb-derived compound tetrandrine shows signs of efficacy in methotrexate-treated patients with moderate to severe rheumatoid arthritis, but placebo rates are high. Medscape Medical News source https://www.medscape.com/viewarticle/tetrandrine-trialed-novel-rheumatoid-arthritis-treatment-2026a1000iya?src=rss

The amylin analog petrelintide reduces body weight with 'placebo-like' tolerability, a phase 2 trial shows. Medscape Medical News source https://www.medscape.com/viewarticle/petrelintide-tolerability-could-improve-glp-1-challenges-2026a1000iy7?src=rss

Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds. Medscape Medical News source https://www.medscape.com/viewarticle/selective-jak1-inhibitor-zemprocitinib-hits-efficacy-targets-2026a1000iy3?src=rss

Low-dose naltrexone does not provide real clinical benefit for patients with fibromyalgia compared to placebo, according to a clinical trial. Medscape Medical News source https://www.medscape.com/viewarticle/low-dose-naltrexone-fails-outperform-placebo-pain-2026a1000iy0?src=rss

In patients with psoriatic arthritis, long-term bimekizumab treatment shows sustained improvement in symptoms and disease impact, according to an analysis of data from two phase 3 trials. Medscape Medical News source https://www.medscape.com/viewarticle/bimekizumab-gives-lasting-symptom-relief-patients-psoriatic-2026a1000itb?src=rss

Early data from the ANISE-II study show that the lupus-approved treatment may also work well in managing Sjögren disease. Medscape Medical News source https://www.medscape.com/viewarticle/anifrolumab-improves-multiple-sj%C3%B6gren-disease-measures-2026a1000isz?src=rss